Search company, investor...

NextWave Pharmaceuticals

nextwavepharma.com

Founded Year

2005

Stage

Acquired - II | Acquired

Total Raised

$95M

About NextWave Pharmaceuticals

NextWave Pharmaceuticals a specialty pharmaceutical company primarily focused on the development and commercialization of products for the treatment of ADHD and related CNS disorders. NextWave's flagship drug, Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, is used for the treatment of ADHD.

Headquarters Location

20450 Stevens Creek Boulevard Suite 150

Cupertino, California, 95014,

United States

408-342-1300

Missing: NextWave Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NextWave Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NextWave Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NextWave Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest NextWave Pharmaceuticals News

Tris Pharma acquires Pfizer’s subsidiary NextWave Pharmaceuticals

Sep 26, 2018

X Tris Pharma, a developer of technology-based therapeutic products, has acquired Pfizer’s subsidiary NextWave Pharmaceuticals for an undisclosed sum. Photo: courtesy of adamr / FreeDigitalPhotos.net. Subscribe to our email newsletter The acquisition of NextWave will allow Tris Pharma to expand its products for the treatment of patients with attention deficit hyperactivity disorder (ADHD). ADHD is a common neurodevelopmental disorder characterized by an ongoing pattern of inattention or hyperactivity and impulsivity. As per the Centers for Disease Control and Prevention’s 2011 data, around 11% of children aged four to 17 years in the US have received an ADHD diagnosis at some stage of their life. Tris Pharma president and CEO Ketan Mehta said: “As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialization of these products in house and expand our ADHD portfolio. “To further support our newest acquisition, Tris is expanding our commercial footprint and building a world class medical affairs group.” Under the deal, Tris will acquire two ADHD treatments, including Quillivant XR and QuilliChew ER, from NextWave. Quillivant XR is the first and only marketed extended-release oral liquid methylphenidate, while and QuilliChew ER is the first and only extended-release methylphenidate chewable tablet. Both products, which are central nervous system (CNS) stimulants, secured approval for the treatment of ADHD. With the support of Tris’ LiquiXR platform, the Quillivant XR and QuilliChew ER products have been developed by NextWave and Tris. Pfizer acquired NextWave in 2012, while Tris continued to produce both products for Pfizer, before and after US Food and Drug Administration (FDA) approval. Tris chief medical officer Dr Barry Herman said: “Our newest acquisition brings us one step closer to realizing our corporate mission, to develop and expand offerings to meet unmet needs for all patients.” Tris Pharma is engaged in the development of pharmaceutical science and technology-based products. It mainly focuses on the research, development, manufacturing and commercialization of both branded and specialty generic products. In 2016, Tris launched Dyanavel XR, which is the first liquid amphetamine for children six years and older with ADHD. Related

NextWave Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was NextWave Pharmaceuticals founded?

    NextWave Pharmaceuticals was founded in 2005.

  • Where is NextWave Pharmaceuticals's headquarters?

    NextWave Pharmaceuticals's headquarters is located at 20450 Stevens Creek Boulevard, Cupertino.

  • What is NextWave Pharmaceuticals's latest funding round?

    NextWave Pharmaceuticals's latest funding round is Acquired - II.

  • How much did NextWave Pharmaceuticals raise?

    NextWave Pharmaceuticals raised a total of $95M.

  • Who are the investors of NextWave Pharmaceuticals?

    Investors of NextWave Pharmaceuticals include Tris Pharma, Pfizer, Vivo Capital, Sofinnova Ventures, Aisling Capital and 6 more.

  • Who are NextWave Pharmaceuticals's competitors?

    Competitors of NextWave Pharmaceuticals include United Biomedical, PrevaCept Infection Control, Itaconix, AkaRx, Pozen and 12 more.

Compare NextWave Pharmaceuticals to Competitors

S
SyntheMed

SyntheMed, Inc. is a biomaterials company dedicated to developing and marketing proprietary polymer products used to prevent or reduce adhesions that may form in a a broad range of surgical procedures.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

F
Funxional Therapeutics

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

A
AkaRx

AkaRx develops therapeutic products including avatrombopag, which is an investigational oral thrombopoietin receptor agonist.

P
Pet Medicus Laboratories

Pet Medicus Laboratories is a specialty pharmaceutical company that is engaged in the formulation, clinical testing, federal registration, manufacture, and sale of drug products for the companion animal market.

S
Savior Lifetec

Savior Lifetec is engaged in the development & manufacture of high quality sterile API (Active Pharmaceutical Ingredients) especially carbapenem antibiotics for generic drug markets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.